ArticleBritish journal of clinical pharmacology2025
Cefuroxime axetil dosing regimens and probability of target attainment in adults and children.
Article in British journal of clinical pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Antibiotic resistance in E.coli isolated from mint in local markets in Hebron, Palestine.BMC microbiology · 2026Article
- Reflections on the Theoretical Prerequisites for Initial Oral Antibiotic Treatment for Paediatric Bone and Joint Infections: A Narrative Review.Antibiotics (Basel, Switzerland) · 2026Review
- Cefuroxime axetil dosing regimens and probability of target attainment in adults and children.British journal of clinical pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
aimsCefuroxime axetil exists in several dosage forms for oral administration, and is indicated for treatment of respiratory, genitourinary, skin and soft tissue infections. Evolving patterns of bacterial susceptibility, expressed as increasing minimum inhibitory concentrations (MICs), warrant monitoring of antibiotic efficacy. Here we investigate the performance of different cefuroxime axetil doses required to yield the desired target exposure against the predominant pathogens for each indication.
methodsThe pharmacokinetics of cefuroxime in plasma/serum and urine was characterized after oral, intravenous and intramuscular administration. Covariates included the effect of weight on clearance and volume of distribution, and formulation on absorption parameters. Subsequently, systemic cefuroxime concentrations over time were simulated to assess the time above the MIC (T > MIC) and the probability of target attainment (PTA) for different dosing regimens in adults and children.
resultsTablet doses of 250 and 500 mg twice daily achieved the target T > MIC (40%) and PTA (≥90%) for MICs up to 0.25 and 0.5 mg/L, respectively, thereby covering most European Committee on Antimicrobial Susceptibility Testing breakpoints for key pathogens. Due to its absorption profile, the oral suspension covers even higher MICs, up to 1.0 mg/L. As cefuroxime is mostly excreted unchanged in urine, cefuroxime axetil doses of 250 mg twice daily for urinary tract infection yield a PTA of 100% for MIC values up to 8 mg/L.
conclusionsOur analysis provides insight into the performance of different doses and dosing regimens for cefuroxime axetil for key pathogens. As resistance patterns evolve, and differ between countries or regions, cefuroxime doses may require adjustments considering local bacterial susceptibility.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.